Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease have?
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease has 139 citations in the OpenAlex counts ScholarIQ stores.
When was Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease published?
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease has 2015 year in the ScholarIQ index.
What is the open-access status of Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease?
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease has closed oa status in the ScholarIQ index.
What is the DOI of Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease?
The DOI for Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease is on the source record.
What is the PMID of Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease?
The PMID for Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease is on the source record.
What is the OpenAlex record for Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease?
The OpenAlex for Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease is on the source record.